Orthofix Medical (OFIX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.07
- Estimate
- -$0.03
- Surprise
- +334.0%
- Revenue (period 2026-06-30)
- $210.9M
- Score at report (before → after)
- 5.0 → 5.0/10
Revenue source: xbrl.
How the report landed
Orthofix Medical (OFIX) beat the -$0.03 estimate with diluted EPS of $0.07 — a large 334.0% upside surprise. TrendMatrix's engine moved from Hold (5.0/10) to Sell at 5.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OFIX Hold at 5.0/10.
3 of the last 4 quarters beat the estimate; this quarter's +334.0% surprise compares with a +104.3% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: Global Spine segment (84.0%)
- Market cap $367M below $400M minimum
- Momentum score 4.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.90
- Price target
- $11.05
- Stop
- $8.36
- Upside to target
- +24.2%
- Reward-to-risk
- 3.4:1
Risk check: RSI 28 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
OFIX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $367.4M
- P/E (fwd)
- 24.6
- 52-week range
- $8.62–$16.99
- Off 52-week high
- 47.6%
- RSI (14)
- 28
- Volume vs avg
- 0.75×
- Score today
- 5.0/10